Acquisition

TDAC, ProLogium amend SPAC merger at $3.9B equity value

What's the deal? Translational Development Acquisition Corp. (TDACDealroom has a profile for this one. Try Dealroom →) and ProLogium Technology have amended their merger agreement, setting ProLogium's equity value at $3.9 billion. The revision, signed November 16, 2026, was disclosed in a Form 8-K filed November 20, 2026, amending a business combination agreement originally dated May 27, 2026.

The terms: The $3.9 billion equity value comprises a $3.8 billion enterprise value plus $100 million in agreed net cash. Aggregate company shares are fixed at 93,682,924, with a consolidation factor of 4.16 governing how existing ProLogium shares convert during recapitalization.

How the shares convert: The amendment replaces the original consolidation mechanics with a share exchange on the closing date. Founder Parties' shares convert to Class B ordinary shares, certain investors including the SBCVC Shareholder and New Epoch Capital LP receive Class C shares, and all other holders get Class A shares.

The structure: Post-closing, a three-class share structure takes effect — Class A shares carry one vote each, Class B shares twelve votes each, and Class C shares two votes each. A nine-member board will be split into three classes, with ProLogium founder Yang Szu-Nan designating three directors including himself, and Michael B. Hoffman expected to serve as the TDAC-designated Class I director.

Why now? The amendment refines the financial and governance terms of a deal first struck in May, tightening the valuation framework and voting rights ahead of closing.

The signal: The revised merger ties ProLogium's listing to a defined valuation and a founder-weighted voting structure, signalling continued appetite for taking battery-technology firms public through SPAC combinations.

Read more: kalkine.com

Image credit: ProLogium Technology

More top stories